BIORA THERAPEUTICS INC (BIOR) Stock Fundamental Analysis

NASDAQ:BIOR • US74319F3055

0.5597 USD
-0.79 (-58.54%)
At close: Dec 10, 2024
0.579 USD
+0.02 (+3.45%)
After Hours: 12/10/2024, 8:09:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BIOR. BIOR was compared to 520 industry peers in the Biotechnology industry. BIOR may be in some trouble as it scores bad on both profitability and health. BIOR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BIOR has reported negative net income.
  • In the past year BIOR has reported a negative cash flow from operations.
  • In the past 5 years BIOR always reported negative net income.
  • In the past 5 years BIOR always reported negative operating cash flow.
BIOR Yearly Net Income VS EBIT VS OCF VS FCFBIOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -217.44%, BIOR is doing worse than 91.15% of the companies in the same industry.
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROIC N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOR Yearly ROA, ROE, ROICBIOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

  • BIOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOR Yearly Profit, Operating, Gross MarginsBIOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1M -2M -3M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BIOR has been reduced compared to 1 year ago.
  • Compared to 1 year ago, BIOR has an improved debt to assets ratio.
BIOR Yearly Shares OutstandingBIOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BIOR Yearly Total Debt VS Total AssetsBIOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -116.59, we must say that BIOR is in the distress zone and has some risk of bankruptcy.
  • BIOR has a worse Altman-Z score (-116.59) than 98.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.59
ROIC/WACCN/A
WACC2.47%
BIOR Yearly LT Debt VS Equity VS FCFBIOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.05, BIOR is doing worse than 99.29% of the companies in the same industry.
  • A Quick Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
  • The Quick ratio of BIOR (0.05) is worse than 99.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
BIOR Yearly Current Assets VS Current LiabilitesBIOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • BIOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.72%.
  • BIOR shows a strong growth in Revenue. In the last year, the Revenue has grown by 8820.00%.
  • The Revenue for BIOR have been decreasing by -87.44% on average. This is quite bad
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 24.30% on average over the next years. This is a very strong growth
  • BIOR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 933.87% yearly.
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIOR Yearly Revenue VS EstimatesBIOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
BIOR Yearly EPS VS EstimatesBIOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • BIOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BIOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOR Price Earnings VS Forward Price EarningsBIOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOR Per share dataBIOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • BIOR's earnings are expected to grow with 24.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.19%
EPS Next 3Y24.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIORA THERAPEUTICS INC

NASDAQ:BIOR (12/10/2024, 8:09:45 PM)

After market: 0.579 +0.02 (+3.45%)

0.5597

-0.79 (-58.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners38.19%
Inst Owner Change0%
Ins Owners0.61%
Ins Owner Change0%
Market Cap2.53M
Revenue(TTM)892.00K
Net Income(TTM)-31.54M
Analysts82.86
Price Target34.68 (6096.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.44%
Min EPS beat(2)-28.34%
Max EPS beat(2)139.22%
EPS beat(4)2
Avg EPS beat(4)44.55%
Min EPS beat(4)-28.34%
Max EPS beat(4)139.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)248.72%
EPS NQ rev (1m)10.81%
EPS NQ rev (3m)-695.18%
EPS NY rev (1m)-2.43%
EPS NY rev (3m)-924.29%
Revenue NQ rev (1m)-54.55%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.46%
Revenue NY rev (3m)-23.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.84
EYN/A
EPS(NY)-7.46
Fwd EYN/A
FCF(TTM)-10.22
FCFYN/A
OCF(TTM)-10.16
OCFYN/A
SpS0.2
BVpS-23.59
TBVpS-24.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.81%
Cap/Sales 31.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -116.59
F-Score4
WACC2.47%
ROIC/WACCN/A
Cap/Depr(3y)55.03%
Cap/Depr(5y)64.29%
Cap/Sales(3y)970%
Cap/Sales(5y)1076.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A
EBIT growth 1Y9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.32%
EBIT Next 3Y-5.74%
EBIT Next 5YN/A
FCF growth 1Y50.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.85%
OCF growth 3YN/A
OCF growth 5YN/A

BIORA THERAPEUTICS INC / BIOR FAQ

What is the fundamental rating for BIOR stock?

ChartMill assigns a fundamental rating of 2 / 10 to BIOR.


What is the valuation status of BIORA THERAPEUTICS INC (BIOR) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIORA THERAPEUTICS INC (BIOR). This can be considered as Overvalued.


What is the profitability of BIOR stock?

BIORA THERAPEUTICS INC (BIOR) has a profitability rating of 0 / 10.